Clinical trial NCT06144866: Evaluataion of NOAC Levels in Acute Stroke
Official title: Evaluation of Non-Vitamin K Antagonist Oral Anticoagulants Concentration Among Patients With Acute Stroke (The Direct Oral AntiCoagulant Registry in Taiwan-Emergent Department, DOACT-ED)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Ischemic Stroke
Anticoagulant Adverse Reaction
Keywords: Ischemic stroke
Intracranial hemorrhage
Direct oral anticoagulant
Drug level
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2023-11-22
Enrollment: 1000
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient under direct oral anticoagulant therapy and suffered from ischemic stroke or intracranial hemorrhage.

Brief summary: Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended over warfarin in preventing stroke and thromboembolism among patients with atrial fibrillation (AF) in several guidelines. To evaluate the pharmacological effects of NOACs, directly measuring the concentration is the most arbitrary way since the correlation between concentration and common coagulation tests are not reliable. Our previous investigation reported under the fixed dose regimen, dabigatran exposure increased in elderly, renal impairments and patients with multiple co-morbid conditions. Our data also showed difference in NOACs exposure in Asians. For example, patients under rivaroxaban, in comparison to apxiaban, were more likely to have lower than expected range drug level. Furthermore, the NOACs concentration also affected by the prescription pattern of physicians (non-compliant to labeled dose) and patients' behavior (poor medication adherence).

The relationship between NOACs exposure and safety has been elucidated in large-scale clinical trials. As the NOACs level increased, the risk for bleeding increased, too. Nevertheless, no additional protection was noted with increased NOACs levels. In post marketing surveillance, bleeding and thrombotic events have been reported. Investigating the NOACs level among these patients helps evaluating the residual drug in the body, which could be a reference for clinical decision in emergent situation.

Specific purpose: Investigate the correlation between NOACs concentration upon the arrival of emergency department (ED) and important clinical outcomes including systemic thromboembolism, and major bleeding.

Direction for investigation:

1. Prospectively record the NOACs concentration among AF patients under NOACs therapy and suffered from ischemic stroke (IS), transient ischemic attack (TIA), intracerebral hemorrhage (ICH) and other major bleeding.
2. Investigate the correlation between NOACs concentration upon ED arrival and thromboembolic or bleeding events.
3. Propose a therapeutic range for NOACs, in order to provide a guide for important decision in acute setting.

Detailed description: Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended over warfarin in preventing stroke and thromboembolism among patients with atrial fibrillation (AF) in several guidelines. To evaluate the pharmacological effects of NOACs, directly measuring the concentration is the most arbitrary way since the correlation between concentration and common coagulation tests are not reliable. Our previous investigation reported under the fixed dose regimen, dabigatran exposure increased in elderly, renal impairments and patients with multiple co-morbid conditions. Our data also showed difference in NOACs exposure in Asians. For example, patients under rivaroxaban, in comparison to apxiaban, were more likely to have lower than expected range drug level. Furthermore, the NOACs concentration also affected by the prescription pattern of physicians (non-compliant to labeled dose) and patients' behavior (poor medication adherence).

The relationship between NOACs exposure and safety has been elucidated in large-scale clinical trials. As the NOACs level increased, the risk for bleeding increased, too. Nevertheless, no additional protection was noted with increased NOACs levels. In post marketing surveillance, bleeding and thrombotic events have been reported. Investigating the NOACs level among these patients helps evaluating the residual drug in the body, which could be a reference for clinical decision in emergent situation.

Specific purpose:

1. Prospectively record the NOACs concentration among AF patients under NOACs therapy and suffered from IS, TIA, ICH or major bleeding.

   AF patients who presented to emergent department (ED) for acute IS, TIA, ICH (non-traumatic), or other major bleeding and was under NOACs therapy will be recruited to this study. Blood sample will be collected before acute management to measure NOACs concentration. Co-morbid disease, laboratory tests and concurrent medications will be retrieved from electronic medical records. The onset, location, severity of IS. ICH or other major bleeding, and the outcome and long-term managements will be prospectively recorded.
2. Investigate the correlation between NOACs concentration and thromboembolic or bleeding events.

   For each NOACs, we are going to compare the differences in NOACs exposure between patients with thromboembolism or major bleedi. Important baseline characteristics, co-medications and disease severity will be adjusted before making comparison.
3. Propose a therapeutic range for NOACs, in order to provide a guide for important decision in acute setting.

From the data of NOACs concentration among patients with IS or ICH, we plan to propose a therapeutic range with acceptable efficacy and safety for NOACs therapy. Our data will provide a guide for physicians to make important clinical decision.

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 20 years
2. Having AF diagnosis
3. Under NOACs therapy including dabigatran, rivaroxaban, apixaban and edoxaban.
4. Admitted for acute IS, transient ischemic attack (TIA), ICH or major bleeding

Exclusion Criteria:

1. The ICH is resulted from trauma.
2. Decline the inform consent.

Primary outcomes:
measure: Functional outcome
timeFrame: 3 months after stroke (ischemic or hemorrhagic)
Secondary outcomes:
measure: Symptomatic intracranial hemorrhage (sICH)
timeFrame: 24-36 hours after stroke
measure: Early neurological improvement
timeFrame: 24 hours after stroke
measure: Successful reperfusion (in ischemic stroke patients receiving endovascular thrombectomy)
timeFrame: Evaluated after EVT
measure: Recurrent ischemic stroke
timeFrame: 3 years
measure: Recurrent intracranial hemorrhage
timeFrame: 3 years
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Shin Yi Lin, M.S.
role: PRINCIPAL_INVESTIGATOR
References: